Evommune, Inc. Short-term Lease, Cost
Evommune, Inc. (EVMN) reported Short-term Lease, Cost of $547.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ShortTermLeaseCost · last filed 2026-08-06
- Evommune, Inc. short-term lease, cost for the quarter ending 2026-06-30 was $258.00K, a 5.84% decline year-over-year.
- Evommune, Inc. short-term lease, cost for the quarter ending 2026-03-31 was $289.00K, a 11.58% increase year-over-year.
- Evommune, Inc. short-term lease, cost for the quarter ending 2025-12-31 was $241.00K, a 16.03% decline year-over-year.
- Evommune, Inc. short-term lease, cost for the quarter ending 2025-09-30 was $301.00K.
- Evommune, Inc. short-term lease, cost for fiscal 2025 was $1.07M, a 12.68% increase from fiscal 2024.
- Evommune, Inc. short-term lease, cost for fiscal 2024 was $954.00K.
| Period end | Short-term Lease, Cost 3 month | Short-term Lease, Cost 6 month | Short-term Lease, Cost 9 month | Short-term Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $258.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $547.00K 10-Q · filed 2026-08-06 | $788.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $289.00K 10-Q · filed 2026-05-07 | $530.00K derived: sum of 2 quarters · filed 2026-05-07 | $831.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $241.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $542.00K derived: sum of 2 quarters · filed 2026-03-05 | $816.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.07M 10-K · filed 2026-03-05 |
| 2025-09-30 | $301.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-12-11 | $575.00K derived: sum of 2 quarters · filed 2026-08-06 | $834.00K 10-Q · filed 2025-12-11 | $1.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $274.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $533.00K 10-Q · filed 2026-08-06 | $820.00K derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-03-31 | $259.00K 10-Q · filed 2026-05-07 | $546.00K derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $287.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $954.00K 10-K · filed 2026-03-05 | ||
| 2024-09-30 | $667.00K 10-Q · filed 2025-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |